Chemo with or without radiation after pancreatic cancer surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial compares adding radiation to chemotherapy versus chemotherapy alone after surgery for pancreatic cancer. It is for people whose cancer had certain high-risk features found during surgery, and who have not yet started additional treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with pancreatic ductal adenocarcinoma (a common type of pancreatic cancer).
- Your surgery showed cancer in nearby lymph nodes, or cancer cells at the edge of what was removed, or cancer cells in blood or lymph vessels.
- You have not had any cancer treatment after your surgery.
- Your recent scans show no signs of cancer growth or spread.
- You are in good overall health (ECOG score 0 or 1) and your blood tests are within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
This trial tests a new chemotherapy combination (HR070803 plus two other drugs) given after surgery to see if it prevents pancreatic cancer from coming back better than the current standard treatment.
This trial tests whether combining radiation therapy with chemotherapy (called the GX regimen) after pancreatic cancer surgery helps prevent cancer from returning in patients with high-risk features. The study aims to see if this combination treatment improves outcomes compared to standard care.
This clinical trial tests whether a combination of chemotherapy drugs (liposomal irinotecan, oxaliplatin, and S-1) is more effective than another standard chemotherapy combination (gemcitabine plus capecitabine) after surgery for pancreatic cancer. It aims to help prevent the cancer from coming back.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.